Low-cost Imaging Technology for Global Prevention of Cervical Cancer

Launched by BARRETOS CANCER HOSPITAL · Oct 4, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on developing a new, low-cost device called the Multimodal Mobile Colposcope (MMC) to help prevent cervical cancer, especially in low-resource settings where there is a shortage of medical professionals and diagnostic services. Cervical cancer is a significant health issue for women in many countries, and this study aims to improve the way we screen and diagnose cervical conditions. The MMC combines two types of imaging technology to provide better and more accurate results during examinations.

To participate in this trial, women over the age of 25 who are undergoing a colposcopy (a procedure to closely examine the cervix) for abnormal screening results or a history of cervical changes may be eligible. Participants will need to be willing to give informed consent and must not be pregnant or nursing. Throughout the study, participants can expect to undergo the colposcopy procedure using the new device and contribute to important research that could improve cervical cancer prevention efforts worldwide.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women \>25 years of age;
• • Women undergoing colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia;
• • Women of childbearing potential must have a negative urine or blood pregnancy test;
• • Ability to understand and willingness to provide informed consent by signing specific Informed Consent Document.
• Exclusion Criteria:
• • Women under 25 years of age;
• • Women who have undergone hysterectomy with removal of the cervix;
• • Women with known allergy to proflavine or acriflavine;
• • Women who are pregnant or nursing at the time of enrollment;
• • Incapacitated women or in vulnerable situations or who are not willing to give consent;